On July 30, 2020, Scott M. Lassman served as the facilitator for a session on "Orphan Drugs: Interesting Cases and New Developments" at FDLI's popular Law Over Lunch series.
Scott M. Lassman will be participating in a panel discussion on June 19, 2020 on Hot Topics in Drug and Medical Device Regulation, which is part of Washington College of Law's Virtual Summer Series on Health Law and Policy (co-sponsored by the American Health Law Association). He will be presenting on new developments regarding orphan drug exclusivity.
Chambers USA recently recognized Scott M. Lassman as a leading attorney (Band 2) in the category of Healthcare: Pharmaceutical/Medical Products Regulatory. Chambers USA specifically highlighted his ability to provide practical solutions to complex regulatory issues, his efficiency, and his "deep knowledge of Hatch-Waxman."
Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation conference on April 1, 2020.
Scott M. Lassman participated in a panel discussion entitled Biosimilars at the Bar at AAM's GRx+Biosims Conference on November 4, 2019. The panel discussed recent legal developments affecting biosimilars, including interchangeability, labeling carve-outs, enhancements to the Purple Book and regulatory pathways for approval of "biobetters."